Sarepta FDA Gene Therapy Issues - Search News

Order byBest matchMost fresh

News

Sarepta, FDA and gene therapy

BioPharma Dive · 5d

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency could still carry major consequences for the Duchenne community.

Continue reading

· 4d · on MSN

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

Fierce Pharma2d

FDA weighs new study requirements for Sarepta to confirm safety of gene therapy Elevidys: report

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

2don MSN

Sarepta drops as report suggests FDA needs new trials for Elevidys

Sarepta Therapeutics (NASDAQ:SRPT) resumed its recent sell-off on Thursday after Endpoints News reported that the FDA would ...

Fierce Biotech5d

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results